ClinicalTrials.gg
RecruitingNCT07221227ZENITH-1Updated Jul 27, 2026

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

A Phase 3 interventional study of Efimosfermin alfa and Efimosfermin alfa in Non-alcoholic Fatty Liver Disease, sponsored by GlaxoSmithKline. Recruiting at 91 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Planned enrollment
15th of 460
1,200 · median 56
Started
2025
with 15 others
Phase 3
29 of 547
7 open now
Primary completion
2028-03
later than 56 of 92 live
Registered
536th of 547
by date
Lead sponsor
8 of 547
GlaxoSmithKline

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 15th largest by planned enrollment of the 460 interventional ones that give a count, is one of 16 that started in 2025, is one of 29 in phase 3, reaches primary completion later than 56 of the 92 other live ones, and was the 536th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease

Keywords

  • Efimosfermin Alfa
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Non-alcoholic Fatty Liver Disease
  • ZENITH-1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to understand and sign a written form that must be obtained prior to the initiation of study procedures
  2. Age >=18 and \<=75 years at enrollment
  3. History or presence of 2 or more of the 5 components of metabolic syndrome per American Heart Association definition
  4. Liver confirmation of MASH consistent with stage F2 or F3 fibrosis and a NAS score >=4 confirmed by a central pathologist

Exclusion criteria

Exclusion Criteria:

  1. or ineligibility for percutaneous liver
  2. or AST >=5 x (ULN)
  3. Total >=1.3 milligram per deciliter (mg/dL). Individuals with documented Gilbert's syndrome may be enrolled if they experienced an isolated increase in total bilirubin of >=1.3 mg/dL and direct bilirubin is \<=20% of total bilirubin; otherwise, the individual will be excluded.
  4. Serum albumin \<=3.5 grams per deciliter (g/dL)
  5. (INR) >=1.3 not due to therapeutic anticoagulation. Individuals receiving chronic anticoagulant treatment with higher INR values may be enrolled at the discretion of the Investigator and Study Medical Monitor.
  6. Alkaline phosphatase (ALP) >=2*ULN
  7. (PLT) count \<140,000 per (/) cubic millimeter (mm\^3); individuals with a PLT count between 110,000/mm\^3 and 140,000/mm\^3 may be enrolled after discussion with the Study Medical Monitor.
  8. Serum creatinine >=1.5 mg/dL or \<=60 milliliter (mL)/minute (min)/1.73 square meter by Chronic Kidney Disease Epidemiology Collaboration equation
  9. Alpha-fetoprotein >=20 nanogram per milliliter (ng/mL)
  10. >=9.0%
  11. Model for End-Stage Liver Disease score >=12 unless the score is elevated in the absence of liver dysfunction (e.g., Gilbert's syndrome)
  12. Phosphatidyl ethanol (PEth) >=80 ng/mL at Screening
  13. Evidence of infection with any of the following:

    1. ;
    2. virus (detectable HBsAg at Screening);
    3. virus (HCV);
  14. Chronic liver disease from any other cause including, but not limited to, alcoholic liver disease; evidence of portal hypertension; viral hepatitis or any history or evidence of cirrhosis on screening liver biopsy; or decompensated liver disease such as clinical ascites, bleeding gastroesophageal varices, hepatorenal syndrome, or hepatic encephalopathy prior to Screening or Day 1.
  15. Current or history of excessive alcohol intake for >=3 months within the 12-month period prior to Screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Participants receiving dose level 1 of efimosfermin alfa

    Drug: Efimosfermin alfa

  • Experimental
    Participants receiving dose level 2 of efimosfermin alfa

    Drug: Efimosfermin alfa

  • Placebo comparator
    Participants receiving Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52

    Proportion of participants experiencing improvement in fibrosis of greater than or equal to (\>=) 1 stage by MASH clinical research network (CRN) fibrosis scores and no worsening of steatohepatitis (defined as no increase in nonalcoholic fatty liver disease activity score \[NAS\] for ballooning, inflammation, or steatosis) at 52 weeks will be assessed. MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity. NAS score ranges from 0 to 8, higher score indicates worse disease activity.

    Time frame: At Week 52

  2. Proportion of participants experiencing resolution of steatohepatitis reading and no worsening of MASH CRN fibrosis score at Week 52

    Resolution of steatohepatitis is defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS of 0 or 1 for inflammation, 0 for ballooning, and any value for steatosis. NAS score ranges from 0 to 8, higher score indicates worse disease activity. MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity.

    Time frame: At Week 52

  3. Time from randomization to an adjudicated composite liver-related clinical outcome

    Liver-related outcome will comprised of all-cause mortality; transplantation; occurrence of significant hepatic events.

    Time frame: From Randomization (Day 1) to 48 months

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity

    Time frame: At Week 52 and at Month 48

  2. Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity

    Time frame: At Week 52 and at Month 48

  3. Number of participants with Grade 3 and Grade 4 laboratory abnormalities

    Time frame: At Week 52 and at Month 48

  4. Proportion of participants experiencing resolution of steatohepatitis on overall histopathological reading and improvement in liver fibrosis of >=1 stage at Week 52

    Resolution of steatohepatitis is defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis on overall histopathological reading on liver biopsies. Proportion of participants experiencing improvement in fibrosis of \>=1 stage by MASH CRN fibrosis scores and resolution of steatohepatitis on overall histopathological reading at 52 weeks will be assessed. MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity

    Time frame: At Week 52

  5. Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of Steatohepatitis at Month 48

    Proportion of participants experiencing improvement in fibrosis of \>=1 stage by MASH CRN fibrosis scores and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis) at Month 48 will be assessed. MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity. NAS score ranges from 0 to 8, higher score indicates worse disease activity.

    Time frame: At Month 48

  6. Proportion of participants experiencing improvement in fibrosis by >=2 stage and no worsening of Steatohepatitis at Week 52 and Month 48

    Proportion of participants experiencing improvement in fibrosis of \>=2 stage by MASH CRN fibrosis scores and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis) at at Week 52 and Month 48 will be assessed. MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity. NAS score ranges from 0 to 8, higher score indicates worse disease activity

    Time frame: At Week 52 and Month 48

  7. Proportion of participants experiencing resolution of steatohepatitis reading and no worsening of MASH CRN score at Month 48

    Resolution of steatohepatitis is defined as absence of fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS of 0 or 1 for inflammation, 0 for ballooning, and any value for steatosis. NAS score ranges from 0 to 8, higher score indicates worse disease activity. MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity.

    Time frame: At Month 48

  8. Absolute change from Baseline in vibration-controlled transient elastography-liver stiffness measurement (VCTE-LSM)

    Time frame: Baseline (Day 1), Week 52 and Month 48

  9. Percent change from Baseline in VCTE-LSM

    Time frame: Baseline (Day 1), Week 52 and Month 48

  10. Absolute change from Baseline in controlled attenuation parameter (CAP) scores

    The CAP score is measured by FibroScan, will be used to quantify and detect liver fat. CAP less than (\<) 238 decibel-milliwatts (dB/m) indicated no hepatic steatosis, 238 less than or equal to (\<=) CAP \<=259 dB/m denoted mild steatosis, 260 \<=CAP \<=291 dB/m indicated moderate steatosis, and CAP greater than (\>) 291 dB/m denoted severe steatosis.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  11. Percent change from Baseline in CAP scores

    The CAP score is measured by FibroScan, will be used to quantify and detect liver fat. CAP \<238 dB/m indicated no hepatic steatosis, 238 \<=CAP \<=259 dB/m denoted mild steatosis, 260 \<=CAP \<=291 dB/m indicated moderate steatosis, and CAP \>291 dB/m denoted severe steatosis.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  12. Proportion of participants achieving Change from Baseline in VCTE-LSM >=30 percent (%) at Week 52 and Month 48

    VCTE-LSM is a non-invasive test that uses vibration-controlled transient elastography to measure the stiffness of the liver in kilopascal (kPa).

    Time frame: Baseline (Day 1), Week 52 and Month 48

  13. Absolute change from Baseline in magnetic resonance elastography (MRE) scores

    MRE is a non-invasive imaging technique that combine magnetic resonance imaging (MRI) scanning with low-frequency mechanical vibrations to measure the stiffness of liver. MRE scores \<2.5 is normal, 2.5 - 3.0 Normal or inflammation, 3.0 - 3.5 Stage 1-2 fibrosis, 3.5 - 4.0 Stage 2-3 fibrosis, 4.0 - 5.0 Stage 3-4 fibrosis and \> 5.0 Stage 4 fibrosis.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  14. Percent change from Baseline in MRE Score

    MRE is a non-invasive imaging technique that combine MRI scanning with low-frequency mechanical vibrations to measure the stiffness of liver. MRE scores \<2.5 is normal, 2.5 - 3.0 Normal or inflammation, 3.0 - 3.5 Stage 1-2 fibrosis, 3.5 - 4.0 Stage 2-3 fibrosis, 4.0 - 5.0 Stage 3-4 fibrosis and \> 5.0 Stage 4 fibrosis.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  15. Absolute change from Baseline in Enhanced Liver Fibrosis (ELF) Score

    The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers. The ELF score is used as a prognostic marker for disease progression: ELF score \<9.8: Low risk of progression, ELF score 9.8 to \<11.3: Moderate risk of progression and ELF score \>=11.3: High risk of progression.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  16. Percent change from Baseline in ELF Score

    The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers. The ELF score is used as a prognostic marker for disease progression: ELF score \<9.8: Low risk of progression, ELF score 9.8 to \<11.3: Moderate risk of progression and ELF score \>=11.3: High risk of progression.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  17. Proportion of participants experiencing improvement in ELF score of >=0.5

    The ELF score will be calculated using a published algorithm combining the values of a set of extracellular matrix markers. The ELF score is used as a prognostic marker for disease progression: ELF score \<9.8: Low risk of progression, ELF score 9.8 to \<11.3: Moderate risk of progression and ELF score \>=11.3: High risk of progression.

    Time frame: At Week 52 and Month 48

  18. Absolute change from Baseline in hepatic fat fraction (HFF) by MRI-derived proton density fat fraction (PDFF)

    HFF is the percentage of fat in the liver measured by MRI proton density fat fraction technique, which ranges from 0-75%. Greater than 5% is considered extra fat in the liver.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  19. Percent change from Baseline in HFF by MRI-PDFF

    HFF is the percentage of fat in the liver measured by MRI proton density fat fraction technique, which ranges from 0-75%. Greater than 5% is considered extra fat in the liver.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  20. Absolute change from Baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (International units per liter)

    Time frame: Baseline (Day 1), Week 52 and Month 48

  21. Percent change from Baseline in ALT and AST (International units per liter)

    Time frame: Baseline (Day 1), Week 52 and Month 48

  22. Absolute change from Baseline in ALT and AST ratio (ALT/AST)

    ALT/AST ratio is calculated as ALT/AST ratio equal to ALT divided by AST.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  23. Percent change from Baseline in ALT and AST ratio (ALT/AST)

    ALT/AST ratio is calculated as ALT/AST ratio equal to ALT divided by AST.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  24. Proportion of participants experiencing ALT and HFF normalization at Week 52 and Month 48

    Time frame: At Week 52 and Month 48

  25. Proportion of participants experiencing HFF <=5% at Week 52 and Month 48

    HFF is the percentage of fat in the liver measured by MRI proton density fat fraction technique, which ranges from 0-75%. Less than or equal to 5% is considered normal (no significant fatty infiltration (steatosis) in the liver.

    Time frame: At Week 52 and Month 48

  26. Change from Baseline in glycated hemoglobin (HbA1c) (Percentage of HbA1c) in participants with Type 2 Diabetes Mellitus (T2DM)

    Time frame: Baseline (Day 1), Week 52 and Month 48

  27. Change from Baseline in body weight (kilograms)

    Time frame: Baseline (Day 1), Week 52 and Month 48

  28. Change from Baseline in fasting total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)- cholesterol, and triglycerides (Millimoles per liter)

    Time frame: Baseline (Day 1), Week 52 and Month 48

  29. Proportion of participants with antidrug and antiFGF21 antibody (ADA)

    Time frame: At Week 52 and Month 48

  30. Change from Baseline in Chronic Liver Disease Questionnaire-Nonalcoholic Steatohepatitis (CLDQ-NASH) in domain and total score

    CLDQ-NASH is a NASH-specific health-related quality of life (HRQoL) Patient-Reported Outcomes (PRO) designed to assess 6 health domains over 36 items: abdominal symptoms (3 items), activity/energy (5 items), emotional health (9 items), fatigue (6 items), systemic symptoms (6 items) and worry (7 items). The domain scores range from 1 to 7, higher scores indicating better HRQoL. A score of 1 meaning the symptom being assessed is "present always" while a score of 7 means the symptom is "never present". The total score can range from 36 to 252, a higher score corresponds to a better quality of life while a lower score corresponds to a worse quality of life.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  31. Change from Baseline in Short Form-36 (SF-36) component and domain scores at Week 52 and Month 48

    SF-36 is a generic HRQoL PRO designed to assess 8 health domains over 36 items: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health (5 items), mental health (5 items), social functioning (2 items), and vitality (4 items). Each domain is scored from 0 (poorer health) to 100 (better health). SF-36 is scored into 8 domains and 2 component scores: physical component summary (PCS) and mental component summary (MCS). The domain and component scores range from 0 to 100, with higher scores indicating better HRQoL.

    Time frame: Baseline (Day 1), Week 52 and Month 48

  32. Serum drug Concentration of efimosfermin alfa

    Time frame: Up to Month 48

07

Study locations

91 of 91 sites recruiting
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
    Recruiting
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
    Recruiting
  • GSK Investigational Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • GSK Investigational Site
    Arcadia, California 91006, United States
    Recruiting
  • GSK Investigational Site
    Covina, California 91723, United States
    Recruiting
  • GSK Investigational Site
    Folsom, California 95630, United States
    Recruiting
  • GSK Investigational Site
    Los Angeles, California 90057, United States
    Recruiting
  • GSK Investigational Site
    Montclair, California 91763, United States
    Recruiting
  • GSK Investigational Site
    Riverdale, California 30274, United States
    Recruiting
  • GSK Investigational Site
    San Diego, California 92120, United States
    Recruiting
  • GSK Investigational Site
    Santa Maria, California 93458, United States
    Recruiting
  • GSK Investigational Site
    Van Nuys, California 91405, United States
    Recruiting
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
    Recruiting
  • GSK Investigational Site
    Boynton Beach, Florida 33435, United States
    Recruiting
  • GSK Investigational Site
    Cape Coral, Florida 33914, United States
    Recruiting
  • GSK Investigational Site
    Clermont, Florida 34711, United States
    Recruiting
  • GSK Investigational Site
    Fort Myers, Florida 33912, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Homestead, Florida 33033, United States
    Recruiting
  • GSK Investigational Site
    Inverness, Florida 34452, United States
    Recruiting
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
    Recruiting
  • GSK Investigational Site
    Kissimmee, Florida 34744, United States
    Recruiting
  • GSK Investigational Site
    Lakeland, Florida 33803, United States
    Recruiting
  • GSK Investigational Site
    Maitland, Florida 32751, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33135, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33144, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33155, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33156, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33173, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33176, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33184, United States
    Recruiting
  • GSK Investigational Site
    Miami Lakes, Florida 33014, United States
    Recruiting
  • GSK Investigational Site
    Ocala, Florida 34471, United States
    Recruiting
  • GSK Investigational Site
    Palmetto Bay, Florida 33157, United States
    Recruiting
  • GSK Investigational Site
    Sarasota, Florida 34201, United States
    Recruiting
  • GSK Investigational Site
    Marietta, Georgia 30060, United States
    Recruiting
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
    Recruiting
  • GSK Investigational Site
    Bastrop, Louisiana 71220, United States
    Recruiting
  • GSK Investigational Site
    Marrero, Louisiana 70072, United States
    Recruiting
  • GSK Investigational Site
    Kansas City, Missouri 64131, United States
    Recruiting
  • GSK Investigational Site
    Springfield, Missouri 62703, United States
    Recruiting
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
    Recruiting
  • GSK Investigational Site
    Las Vegas, Nevada 89106, United States
    Recruiting
  • GSK Investigational Site
    East Syracuse, New York 13057, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10036, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10036, United States
    Recruiting
  • GSK Investigational Site
    Fayetteville, North Carolina 28304, United States
    Recruiting
  • GSK Investigational Site
    Morehead City, North Carolina 28557, United States
    Recruiting
  • GSK Investigational Site
    Akron, Ohio 44320, United States
    Recruiting
  • GSK Investigational Site
    Springboro, Ohio 45066, United States
    Recruiting
  • GSK Investigational Site
    Westlake, Ohio 44145, United States
    Recruiting
  • GSK Investigational Site
    Chattanooga, Tennessee 37421, United States
    Recruiting
  • GSK Investigational Site
    Arlington, Texas 76012, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78704, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78757, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78759, United States
    Recruiting
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
    Recruiting
  • GSK Investigational Site
    Brownsville, Texas 78526, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75243, United States
    Recruiting
  • GSK Investigational Site
    DeSoto, Texas 75115, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77004, United States
    Recruiting
  • GSK Investigational Site
    Irving, Texas 75061, United States
    Recruiting
  • GSK Investigational Site
    Richmond, Texas 77406, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
    Recruiting
  • GSK Investigational Site
    Seabrook, Texas 77586, United States
    Recruiting
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
    Recruiting
  • GSK Investigational Site
    Tomball, Texas 77375, United States
    Recruiting
  • GSK Investigational Site
    Waco, Texas 76710, United States
    Recruiting
  • GSK Investigational Site
    Waco, Texas 76712, United States
    Recruiting
  • GSK Investigational Site
    West Jordan, Utah 84088, United States
    Recruiting
  • GSK Investigational Site
    Manassas, Virginia 20110, United States
    Recruiting
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
    Recruiting
  • GSK Investigational Site
    Seattle, Washington 98105, United States
    Recruiting
  • GSK Investigational Site
    Broadmeadow, New South Wales 2292, Australia
    Recruiting
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
    Recruiting
  • GSK Investigational Site
    Québec, Quebec G1N 4V3, Canada
    Recruiting
  • GSK Investigational Site
    Pokfulam, Hong Kong
    Recruiting
  • GSK Investigational Site
    Gifu, 503-8502, Japan
    Recruiting
  • GSK Investigational Site
    Kanagawa, 215-0026, Japan
    Recruiting
  • GSK Investigational Site
    Kyoto, 602-8566, Japan
    Recruiting
  • GSK Investigational Site
    Musashino, 180-8610, Japan
    Recruiting
  • GSK Investigational Site
    Yokohama, 236-0004, Japan
    Recruiting
  • GSK Investigational Site
    Wellington, 6021, New Zealand
    Recruiting
  • GSK Investigational Site
    San Juan, 00927, Puerto Rico
    Recruiting
  • GSK Investigational Site
    Riyadh, 11472, Saudi Arabia
    Recruiting
  • GSK Investigational Site
    Chiayi City, 600, Taiwan
    Recruiting
  • GSK Investigational Site
    Kaohsiung City, 80756, Taiwan
    Recruiting
  • GSK Investigational Site
    Kaohsiung City, 83301, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2025
First posted
Oct 27, 2025
StartActual
Oct 24, 2025
Primary completionEst.
Mar 29, 2028
CompletionEst.
Dec 12, 2031
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07221227
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 27, 2025
Start date
Oct 24, 2025
Primary completion
Mar 29, 2028 (estimated)
Completion
Dec 12, 2031 (estimated)
Last update
Jul 27, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efimosfermin alfa

Start the discussion